Ju Feng, Chen Kaixia, Yin Dengyang
Department of Pharmacy Management, Jingjiang People's Hospital, Jingjiang, China.
Clinical Pharmacy Support, Jingjiang People's Hospital, Jingjiang, China.
J Chemother. 2025 Sep;37(5):426-435. doi: 10.1080/1120009X.2024.2385254. Epub 2024 Aug 12.
To assess the efficacy and safety of capecitabine in treating advanced colon cancer. Patients with advanced colon cancer were randomized into three groups: control group ( = 50, daily dose 2,500 mg/m), the medium-dose group ( = 50, daily dose 2,000 mg/m), and the low-dose group ( = 50, daily dose 1,500 mg/m) capecitabine for 4 cycles(12 weeks). Afterwards, the response rate, quality of life, and adverse reactions of the three groups were collected for comparison. Efficacy rates were 50%, 70%, and 72%, respectively, with the low-dose group showing the highest efficacy (χ2 = 6.424, = 0.040); Quality of life comparison results indicated significant differences in physical function ( = 98.528, < 0.001), role function ( = 123.418, < 0.001), social function( = 89.539, < 0.001), emotional function (6 = 77.295, < 0.001), cognitive function ( = 83.529, < 0.001), and overall quality of life ( = 99.528, < 0.001) among the three groups, and the three groups returned consistent scores, with the low-dose group scoring highest. Incidence rates were 86.00%, 46.00%, 34.00%, with the control group having the highest rate (χ = 16.505, < 0.001). Capecitabine at a dosage of 1,500 mg/m demonstrated a good therapeutic effect and improved the quality of life in patients with advanced colon cancer, with a lower incidence of adverse reactions. A prolonged treatment cycle with reduced dosage is suggested to further improve treatment outcomes and patient prognosis. The study was registered on clicaltrials.gov 'NCT06246461' on 30/01/2024.
评估卡培他滨治疗晚期结肠癌的疗效和安全性。将晚期结肠癌患者随机分为三组：对照组（n = 50，每日剂量2500mg/m²）、中剂量组（n = 50，每日剂量2000mg/m²）和低剂量组（n = 50，每日剂量1500mg/m²），给予卡培他滨治疗4个周期（12周）。之后，收集三组的缓解率、生活质量和不良反应进行比较。有效率分别为50%、70%和72%，低剂量组疗效最高（χ² = 6.424，P = 0.040）；生活质量比较结果显示，三组在身体功能（F = 98.528，P < 0.001）、角色功能（F = 123.418，P < 0.001）、社会功能（F = 89.539，P < 0.001）、情感功能（F = 77.295，P < 0.001）、认知功能（F = 83.529，P < 0.001）和总体生活质量（F = 99.528，P < 0.001）方面存在显著差异，且三组得分一致，低剂量组得分最高。发生率分别为86.00%、46.00%、34.00%，对照组发生率最高（χ² = 16.505，P < 0.001）。1500mg/m²剂量的卡培他滨对晚期结肠癌患者显示出良好的治疗效果，提高了生活质量，且不良反应发生率较低。建议延长治疗周期并降低剂量以进一步改善治疗效果和患者预后。该研究于2024年1月30日在clicaltrials.gov上注册，注册号为 'NCT06246461'。
